The MagSense test aims to eliminate the unnecessary surgeries and concomitant morbidity resulting from the standard of care biopsy procedure.
Showing 25 of 3078
Edison Investment Research has assigned an indicative valuation range of $84–135 million or $1.35–2.17 per share for Kazia.
Invex is focused on repurposing an already approved drug, Exenatide, to treat neurological conditions.
The company has a substantial pipeline of future product launches to drive growth in the 2020 financial year.
THC Global operates under a ‘Farm to Pharma’ pharmaceutical model.
Sydney-based Hishenk Pty Ltd now holds 10.835 million shares after placement and on-market purchases.
Non-executive director Chris Fullerton participated in a $26.3 million entitlement offer and has also purchased shares on-market.
To facilitate its ongoing development and growth, the company signed employment agreements with five new staff members in late June.
This second drawdown, together with the cash on hand following a recent $5 million placement, means the company is well funded into 2021.
ColoSTAT has the potential to play an important role in reducing morbidity and mortality rates associated with colorectal cancer.
The study had positive outcomes, showing that the valve replacement devices had good durability.
The company uses its proven protected diamagnetic microarray technology in both skin care and joint inflammation products.
The positive data comes as Orthocell is active in partnering discussions and will support the company to gain traction in key markets.
Monash Health will be the second clinical trial site with the company expecting to sign further hospitals to join the ColoSTAT trial in coming weeks.
The company has been granted a trading halt which will remain in place until the start of trading on June 14 or when an announcement is released to the market.
Maria Halasz has recently lifted her total holding to almost 2.2 million shares through acquiring a further 12,000 shares.
In parallel with the global roll-out of PromarkerD to markets, the company is pursuing registration of the kit version of the test for larger-scale adoption.
The company finished the March quarter with $21 million in the bank.
The new Pronto range of dual action products is set to go on sale in the second half of this year.
The breast cancer and colorectal tests will provide healthcare providers and their patients with risk assessments of the patient developing breast cancer.
The retail entitlement offer had a take-up rate of about 54.7% for acceptances of entitlements and applications for additional shares by eligible retail shareholders.
The company remains in voluntary suspension to facilitate completion of its recapitalisation plan.
The company plans to begin recruitment for its upcoming dose expansion cohort immediately.
The company is waiting final licencing and permitting approvals to begin manufacturing at its Canndeo site in Canada.
The company told Proactive Investors in February that it remained on track for record revenues in financial year 2019, targeting profitability in financial year 2020.